arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Bolt Biotherapeutics, Inc.

BOLT

$4.06 ▲ +0.16 (+4.10%) at close

7 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Bolt Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.6M

Dividend Yield —

Revenue Growth 0.1% ↗

Op. Margin -469.3%

ROIC -136.2% ↘

FCF / Share $-21.35 ↗

Trailing P/E —

Price / Book 0.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.70M

— +0.1% —

Net Income Profit after all expenses

$-33.38M

↑ +47.1% —

FCF / Share Free cash flow per share

$-21.35

↑ +33.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	0.1% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-99%)	-2.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-130%)	37.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+368%)	354.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4334%)	445.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5468%)	—	—
EPS Growth YoY (%)	46.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-36031.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	22.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	20.5% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	47.1% Excellent ↑ Excellent Improving Year-over-year change in net income	8.8% Fair ↑ Fair Improving Year-over-year change in net income	21.5% Good ↑ Good Improving Year-over-year change in net income	10.6% Fair Fair Year-over-year change in net income	-62.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	33.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-34737.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	12.2% Fair ↓ Fair Declining Year-over-year change in free cash flow	-17.4% Weak Weak Year-over-year change in free cash flow	93.0% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	10.3% Good ↓ Good Declining Compound annual revenue growth over 3 years	82.7% Excellent Excellent Compound annual revenue growth over 3 years	224.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	101.6% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-469.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3229%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
Profit Margin (%) (%)	-433.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3714%)	—	—	—	—	—	—
FCF / Net Income (x)	1.20x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-136.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-127.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	37.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-63.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-39.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-105.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-125.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-939%)	-110.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-836%)	-61.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-509%)	-51.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-442%)	-39.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	57.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+286%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-11.70M	$-7.21M	$-10.81M	$-9.24M	$-27.38M	$-5.54M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$4.12	$4.03	$0.01	$0.01	$0.00	$0.01	—
Basic EPS, GAAP (USD)	$-17.85	$-33.06	$-0.09	$-0.12	$-0.15	—	—
Free Cash Flow per Share (USD)	$-21.35	$-32.12	$-0.09	$-0.11	$-0.09	$-1.27	—
Book Value per Share (USD)	$13.80	$29.84	$0.15	$0.23	$0.33	$-2.46	—
Tangible Book Value per Share (USD)	$13.80	$29.84	$0.15	$0.23	$0.33	$-2.46	—
Basic Weighted Avg Shares (shares)	1.87M	1.91M	756.24M	747.17M	663.93M	39.78M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$21.82M	$34.96M	$85.25M	$149.63M	$167.83M	$14.10M	—
Total Equity (USD)	$26.50M	$57.20M	$112.74M	$171.51M	$250.12M	$-104.95M	$-45.85M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$7.70M	$7.69M	$7.88M	$5.73M	$1.26M	$231.00K	—
Depreciation Expense (USD)	$1.29M	$1.78M	$1.85M	$1.67M	$1.19M	$611.00K	—
Net Income, GAAP (USD)	$-33.38M	$-63.12M	$-69.20M	$-88.10M	$-98.59M	$-60.73M	—
Operating Cash Flow (USD)	$-39.85M	$-61.29M	$-69.53M	$-76.50M	$-57.07M	$-47.31M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Bolt Biotherapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BOLT with peers